Oral tolerance in disease

Gut

Volumn 44, Issue 1, 1999, Pages 137-142

  Garside, P ^a   Mowat, A Mc I ^a   Khoruts, A ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE; KEYHOLE LIMPET HEMOCYANIN; OVALBUMIN;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELIAC DISEASE; CROHN DISEASE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INTESTINE LYMPHATIC TISSUE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 0033003599     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.1.137     Document Type: Review

References (112)

1. 1 Mowat AMcI, Viney J. The anatomical basis of intestinal immunity. Immunol Rev 1997;156:145-66.
2. 2 Wells HG, Osborne TB. The biological reactions of the vegetable proteins. I. Anaphylaxis. J Infect Dis 1911;8:66-124
3. 3 Garside P, Mowat AMcI. Mechanisms of oral tolerance. Crit Rev Immunol 1996;17:119-37.
4. 4 Mowat AMcI, Weiner HL. Oral tolerance: basic mechanisms and clinical implications. In: Ogra PL, Mestecky J, Lamm ME, et al, eds. Handbook of mucosal immunology. 2nd edn. San Diego: Academic Press, 1998.
5. 5 Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42.
6. 6 Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-4.
7. 7 Elson CO, Sartor BR, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology 1995;109:1344-67.
8. 8 Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol 1996;12:327-33.
9. 9 Schwanz RH. Acquisition of self-tolerance. Cell 1989;57:1073-81.
10. 10 Dresser, DW. Effectiveness of lipid and lipidophilic substances as adjuvants. Nature 1961;191:1169-71.
11. 11 Vives J, Parks DE, Weigle WO. Immunologic unresponsiveness after gastric administration of human gamma-globulin: antigen requirements and cellular requirements. J Immunol 1980;125:1811-16.
12. 12 Pape KA, Khoruts A, Mondino A, et al. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 1997;159:591-8.
13. 13 Swarbrick ET, Stokes CR, Soothill JF. Absorption of antigens after oral immunization and the simultaneous induction of specific systemic tolerance. Gut 1986;20:121-5.
14. 14 Husby S, Jensenius JC, Svehag SE, et al. Passage of undergraded dietary antigen into the blood of healthy adults. Further characterization of the kinetics of uptake and the size distribution of the antigen. Scand J Immunol 1986;24:447-52.
15. 15 Husby S, Foged K, Host A, et al. Passage of dietary antigens into the blood of children with coeliac disease. Quantification and size distribution of absorbed antigens. Gut 1987;28:1062-72.
16. 16 Whitacre CC, Gienapp IE, Orosz CG, et al. Oral tolerance in experimental autoimmune encephalitis. III. Evidence for clonal anergy. J Immunol 1991; 147:2155-63.
17. 17 Van Houten N, Blake SF. Direct measurement of anergy of antigen-specific T cells following oral tolerance induction. J Immunol 1996;157:1337-41.
18. 18 Baschieri S, Lees RK, Lussow AR, et al. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines. Eur J Immunol 1993;23:2661-6.
19. 19 Chen Y, Inobe J-I, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995;376:177-80.
20. 20 Chen Y, Inobe J-I, Kuchroo VK, et al. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996;93:388-91.
21. 21 Kearney ER, Pape KA, Loh DY, et al. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994;1: 327-39.
22. 22 Chen Y, Inobe J-I, Weiner HL. Inductive events in oral tolerance in the TcR transgenic adoptive transfer model. Cell Immunol 1997;178:62-8.
23. 23 Mowat AM. The regulation of immune responses to dietary protein antigens. Immunol Today 1987;8:93-8.
24. 24 Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265:1237-40.
25. 25 Rock KL, Rothstein L, Fleischacker C, et al. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen. J Immunol 1992;148:3028-33.
26. 26 Garside P, Steel M, Liew EY, et al. CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int Immunol 1995;7:501-4.
27. 27 von Herrath MG, Dryberg T, Oldstone MB. Oral insulin treatment suppresses virus-induced antigen-specific destruction of β cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996;98: 1324-31.
28. 28 Blanas E, Carbone FR, Allison, J, et al. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1997;274:1707-9.
29. 29 Lefrancois L. Basic aspects of intraepithelial lymphocyte immunobiology. In: Ogra PL, Mestecky J, Lamm ME, et al. Handbook of mucosal immunology. 2nd edn. San Diego: Academic Press, 1998.
30. + suppressor T cells. J Immunol 1996;156:916-21.
31. 31 McMenamin C, Pimm M, McKersey M, et al. Regulation of IgE responses to inhaled antigen in mice by antigen-specific γδ T cells. Science 1994;265: 1869-71.
32. 32 Wildner G, Thurau SR. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye. Eur J Immunol 1995;25:1292-7.
33. 33 Boismenu R, Havran WL. Modulation of epithelial cell growth by intraepithelial γδ T cells. Science 1994;266:1253-5.
34. 34 Lycke N, Bromander A, Ekman L, et al. The use of knockout mice in studies of induction and regulation of gut mucosal immunity. Mucosal Immunology Update 1995;3:1-8.
35. 35 Vistica BP, Chanaud NP, Felix N, et al. CD8 T-cells are not essential for the induction of "low dose" oral tolerance. Clin Immunol Immunopathol 1996;78:196-202.
36. + cells mediate active suppression. J Immunol 1995;155:910-16.
37. + cells on the induction and maintenance of oral tolerance. Cell Immunol 1995;163:19-29.
38. + T cell-depleted mice. Eur J Immunol 1996;26:1756-61.
39. + T cells anergized by high dose feeding establish oral tolerance to antibody responses when transferred in SCID and nude mice. J Immunol 1995;154:6238-45.
40. 40 Garside P, Steel M, Worthey EA, et al. TH2 cells are subject to high-dose oral tolerance and are not essential for its induction. J Immunol 1995;154: 5640-55.
41. 41 Wolvers DAW, van der Cammen MJF. Mucosal tolerance is associated with, but independent of, upregulation of Th2 responses. Immunology 1997;92: 328-33.
42. 42 Jarrett EE. Perinatal influences on IgE responses. Lancet 1984;ii:797-9.
43. 43 Khoruts A, Miller SD, Jenkins MK. Neuroamigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol 1995;155:5011-17.
44. 44 Lafaille JJ, Keere FV, Hsu AL, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997; 186:307-12.
45. 45 Ding L, Linsley PS, Huang L-Y, et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the upregulation of B7 expression. J Immunol 1993;3:1224-34.
46. 46 Fiorentino DF, Zlotnik A, Viera P, et al. IL-10 acts on the antigen presenting cell to inhibit cvtokinc production by Th1 cells. J Immunol 1991;146:3444-51.
47. 47 Aroeira LS, Cardillo F, DeAbuquerque DA, et al. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA. Scand J Immunol 1995;41:319-23.
48. 48 Marth T, Strober W, Kelsall BL. High dose oral tolerance in ovalbumin TcR-transgenic mice: systemic neutralisation of interleukin 12 augments TGFβ secretion and T cell apoptosis. J Immunol 1996;157:2348-57.
49. 40 Symington FW. Lymphotoxin, tumor necrosis factor and gamma interferon are cytostatic for normal human keratinocytes. J Invest Dermatol 1989;92:798-805.
50. 50 Mueller DL, Jenkins MK. Molecular mechanisms underlying functional T-cell unresponsiveness. Curr Opin Immunol 1995;7:375-81.
51. 51 Mowat AMcI, Garside P, Fitton LA, et al. Regulatory activity of endogenous and exogenous transforming growth factor β in experimental intestinal immunopathology. Growth Factors 1996;13:75-85.
52. 52 Kim P-H, Kagnoff MF. Transforming growth factor-β1 is a costimulator for IgA production. J Immunol 1990;144:3411-16.
53. 53 Roberts A, Sporn M. Physiological actions and clinical applications of transforming growth factor β (TGFβ). Growth Factors 1993,8:1-9.
54. 54 Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transfroming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-64.
55. 55 Miller A, Lider O, Roberts AB, et al. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992;89:421-5.
56. low CD4+ T cells. J Exp Med 1996;183: 2669-74.
57. 57 Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996;183:2605-16.
58. 58 Strober W, Kelsall B, Fuss I, et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997;18: 61-4.
59. 50 Fishman-Lobell J, Friedman A, Weiner HL. Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice. Eur J Immunol 1994;24:2720-4.
60. 60 Mowat AMcI, Ferguson A. Hypersensitivity in the small intestinal mucosa. V. Induction of cell mediated immunity to a dietary antigen. Clin Exp Immunology 1981;43:574-82.
61. 61 Mowat AMcI. Deletion of suppressor T cells by 2'-deoxyguanosine abrogates tolerance in mice fed ovalbumin and permits the induction of intestinal delayed-type-hypersensitivity. Immunology 1986;58:179-84.
62. 62 Sands BE, Podolsky DK. Toward new questions in inflammatory bowel disease in 1995. Curr Opin Gastroenterol 1996;12:319-21.
63. 63 Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
64. 64 Duchmann R, Schmitt E, Knolle P, et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-8.
65. 65 Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
66. 66 Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-79.
67. 67 Mombaerts P, Mizoguchi E, Grusby MJ, et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:275-82.
68. 68 Moyana TN, Lalonde J-MA Carrageenan-induced intestinal injury in the rat-a model for inflammatory bowel disease. Ann Clin Lab Sci 1990;20:420-6.
69. 69 Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995;270:1203-7.
70. 70 Baribault H, Penner J, Iozzo RV, et al. Colorectal hyporplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev 1994;8:2964-73.
71. 71 Mashimo H, Wu D-C, Podolsky DK, et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996;274:262-5.
72. 72 Sayegh MH, Khoury SJ, Hancock WH, et al. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci USA 1992;89:7762-6.
73. 73 Higgins PJ, Weiner H. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988;140:440-5.
74. 74 Bitar D, Whitacre CC. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell Immunol 1988;112:364-70.
75. 75 Whitacre CC, Gienapp IE, Zhang X, et al. Oral tolerance in experimental autoimmune encephalomyelitis (EAE): A search for the MSB-specific T cell receptor [abstract]. FASEB J 1990;4:A1856.
76. 76 Meyer AL, Benson JM, Gienapp IE, et al. Suppression of murine chronic relapsing autoimmune encephalomyelitis by the oral administration of myelin basic protein. J Immunol 1996;57:4230-8.
77. 77 Yoshino S, Quattrocchi E, Weiner HL. Oral administration of type II collagen suppresses antigen-induced arthritis in Lewis rats. Arthritis Rheum 1995;38:1092-6.
78. 78 Zhang J Z, Lee CSY, Lider O, et al. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990;145: 2489-93.
79. 79 Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II antigen. Proc Natl Acad Sci USA 1986;83:7443-6.
80. 80 Thompson HS, Staines NA. Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today 1990;11:396-9.
81. 81 Thompson HS, Harper N, Bevan DJ, et al. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993;16:189-99.
82. 82 Thompson HS, Staines NA. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin Exp Immunol 1986;64:581-6.
83. 83 Staines NA, Harper N, Ward EJ, et al. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 1996;103:368-75.
84. 84 Thompson SJ, Thompson HS, Harper N, et al. Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology 1993;79:152-7.
85. 85 Nussenblatt RB, Caspi RR, Mahdi R, et al. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990;144:1689-96.
86. 86 Nussenblatt RB, Whitcup SM, De Smet MD, et al. Intraocular inflammatory disease (uveitis) and the use of oral tolerance. A status report. Ann NY Acad Sci 1996;778:325-37.
87. 87 Singh VK, Kalra HK, Yamaki K, et al. Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment ar a cross-reactive homologous peptide. Cell Immunol 1992;139:81-90.
88. 88 Thurau SR, Chan CC, Nusenblatt RB, et al. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis: induction of protective tolerance in primed animals. Clin Exp Immunol 1997;109:370-6.
89. 89 Rizzo LV, Miller-Rivero NE, Chan CC, et al. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 1994;94:1668-72.
90. 90 Drachman DB, Okumura S, Adams RN, et al. Oral tolerance in myaesthenia gravis. Ann NY Acad Sci 1996;778:258-72.
91. 91 Okumura S, McIntosh K, Drachman DB. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol 1994; 36:704-13.
92. 92 Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993;44:209-14.
93. 93 Wang Z-Y, He B, Qiao J, et al. Suppression of experimental autoimmune myasthenia gravis and experimental allergic encephalomyelitis by oral administration of acetylcholine receptor and myelin basic protein: double tolerance. J Neuroimmunol 1995;63:79-86.
94. 94 Zhang JA, Davidson L, Eisenbarth G, et al. Suppression of diabetes in NOD mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991;88:10252-6.
95. 95 Bergerot I, Fioix C, Peterson J, et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:4610-14.
96. + T cells that suppress adoptive transfer of diabetes. J Autoimmunity 1994;7:655-63.
97. 97 Sayegh MH, Zhang ZJ, Hancock WW, et al. Down-regulation of the immune response to histocompatibility antigen and prevention of sensitixation by skin allografts by orally administered alloantigen. Transplantation 1992;53: 163-6.
98. 98 He YG, Mellon J, Niederkorn JY. The effect of oral immunisation on corneal allograft survival. Transplantation 1996;61:920-6.
99. 99 Guimaraes VC, Quintans J, Fisfalen M-E, et al. Suppression of experimental autoimmune thyroiditis by oral administration of thyroglobulin. Endocrinology 1995;136:3353-9.
100. 100 Peterson KE, Braley-Mullen H. Suppression of murine experimental autoimmune thyroiditis by oral administration of porcine thyroglobulin. Cell Immunol 1995;166:123-30.
101. 101 Sieper J, Kary S, Sörensen H, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double blind, placebo-controlled, randomized trial. Arthritis Rheum 1996;39:41-51.
102. 102 Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996;39:623-8.
103. 103 Sun JB, Rask C, Olsson T, et al. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996;93:7196-201.
104. 104 Weiner HL. Oral tolerance: Immune mechanisms and treatment of autoimmune disease. Immunol Today 1997;18:335-43.
105. 105 Husby S, Mestecky J, Moldoveanu Z, et al. Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding. J Immunol 1994;152:4663-70.
106. 106 Waldo FB, Van Den Wall Bake AWL, Mestecky J, et al. Suppression of the immune response by nasal immunization. Clin Immunol Immunopathol 1994;72:30-4.
107. 107 Fukaura H, Kent SC, Pietrusewicz ML, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1-secreting Th3 cells by oral administration of myelin in multiple sclerosis. J Clin Invest 1996,98:70-7.
108. 108 Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of tolerization with myelin antigens in multiple sclerosis. Science 1993;259:1321-24.
109. 109 Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of collagen on rheumatoid arthritis. Science 1993;261:1727-30.
110. 110 Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial. Am J Opthalmol 1997;123:583-02.
111. 111 Metzler B, Wraith DC. Inhibition of experimental autimmunc encephalomyclitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993;5:1159-65.
112. 112 Ma S-W, Zhao D-L, Mukherjee R, et al. Transgenic plants expressing autoantigens fed to mice to induce oral tolerance. Nat Med 1997;3:793-6.